Amgen and Pfizer's PCSK9 inhibitors step hopefully 'down the line'
This article was originally published in Scrip
Further Phase II data supporting a strong efficacy profile for Amgen’s and Pfizer’s PCSK9 inhibitors –AMG 145 and RN316 (PF-04950615) – generated excitement at the American Heart Association meeting in Los Angeles as they make a compelling clinical case for the drugs’ additive effect to statins, raising the hope that in future most patients will be able to reach their LDL-cholesterol goals with this new drug class.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.